GoodRx Holdings Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
GDRX$3.54-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands, except per share amounts) | 2024 | 2023 |
| Revenue | $197,880 | $183,986 |
| Costs and operating expenses: | ||
| Cost of revenue, exclusive of depreciation and amortization presented separately below | 12,468 | 16,695 |
| Product development and technology | 31,017 | 32,908 |
| Sales and marketing | 89,964 | 78,522 |
| General and administrative | 41,108 | 29,619 |
| Depreciation and amortization | 15,942 | 14,939 |
| Total costs and operating expenses | 190,499 | 172,683 |
| Operating income | 7,381 | 11,303 |
| Other expense, net: | ||
| Other expense | — | (1,808) |
| Interest income | 7,555 | 7,234 |
| Interest expense | (14,643) | (13,133) |
| Total other expense, net | (7,088) | (7,707) |
| Income before income taxes | 293 | 3,596 |
| Income tax expense | (1,302) | (6,886) |
| Net loss | $(1,009) | $(3,290) |
| Loss per share: | ||
| Basic and diluted | $(0.00) | $(0.01) |
| Weighted average shares used in computing loss per share: | ||
| Basic and diluted | 390,048 | 412,429 |
| Stock-based compensation included in costs and operating expenses: | ||
| Cost of revenue | $76 | $161 |
| Product development and technology | 5,848 | 8,589 |
| Sales and marketing | 8,127 | 4,412 |
| General and administrative | 11,045 | 12,337 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.